PatentVest (MDBH) released a Pulse report, “The Amylin Renaissance,” on March 31, 2026, detailing a rapid commercialization shift in amylin-based obesity therapies.
The report documents nearly 40 amylin receptor agonist programs, more than $19 billion in deal value committed over the past 18 months, clinical data showing up to 20%+ weight loss, an approaching FDA decision for a GLP-1/amylin combo, and growing oral small-molecule efforts. It emphasizes patent strategy as a decisive competitive factor.
Loading...
Loading translation...
Positive
$19 billion in deal value committed across the amylin space
Nearly 40 amylin receptor agonist programs in development worldwide
Clinical data reporting up to 20%+ weight loss with amylin-based therapies
GLP-1/amylin combination therapy approaching an FDA decision
High capital intensity: over $19 billion committed in past 18 months
News Market Reaction – MDBH
+1.71%1.9x vol
3 alerts
+1.71%Session close to close
$32.96MMarket Cap
1.9xRel. Volume
In the Mar 31 session, MDBH gained 1.71%, reflecting a mild positive market reaction.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
This announcement underscores MDBH’s PatentVest unit as an IP intelligence provider at the center of...
Analysis
This announcement underscores MDBH’s PatentVest unit as an IP intelligence provider at the center of obesity drug innovation. The report profiles nearly 40 amylin programs, over $19 billion in deal value, and efficacy signals up to 20%+ weight loss, emphasizing how patent depth shapes long-term winners. In context with MDBH’s broader IP and public venture strategy, investors may watch how such research supports new mandates, partner formation, and potential fee or equity economics across emerging obesity and metabolic pipelines.
Key Figures
Amylin deal value:$19 billionAmylin programs:Nearly 40Weight loss efficacy:Up to 20%++2 more
5 metrics
Amylin deal value$19 billionCommitted across amylin space in past eighteen months
Amylin programsNearly 40Amylin receptor agonist programs in development worldwide
Weight loss efficacyUp to 20%+Clinical data for amylin-based obesity therapies
Outlook horizonNext 18 monthsPeriod highlighted for key clinical and regulatory events
Market cap$30,212,109MDBH market capitalization before this news
PatentVest report on IP landscape shaping the $1.8 trillion space economy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
MDBH news around PatentVest reports and partnerships often produced modest, sometimes contrary, price reactions, while broader thematic reports and certain corporate updates have coincided with stronger upside.
Recent Company History
Over the past six months, MDBH has highlighted its role via PatentVest in IP analytics across obesity, GLP-1, and the space economy, alongside governance and earnings-related updates. Events such as the space IP report on Jan 14, 2026 and the Q4/FY 2025 call announcement on Mar 23, 2026 saw positive reactions, while IP-focused collaborations and GLP-1 reporting triggered mild declines. Today’s amylin-focused Pulse report extends this pattern of thematic IP insights tied to major biotech trends.
Key Terms
amylin, glp-1, fda, oral small-molecule, +2 more
6 terms
amylinmedical
"the rapidly evolving amylin drug landscape, a mechanism once considered commercially"
Amylin is a naturally occurring hormone released by the pancreas alongside insulin that helps control blood sugar by slowing how quickly the stomach empties and by reducing signals that raise blood glucose. For investors, amylin matters because drugs that mimic or modify its action are a major avenue for treating diabetes and obesity, so clinical progress, approvals or safety data for amylin-based therapies can significantly affect pharmaceutical valuations and market opportunity.
glp-1medical
"The first GLP-1/amylin combination therapy approaching FDA decision"
GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.
fdaregulatory
"The first GLP-1/amylin combination therapy approaching FDA decision"
The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.
oral small-moleculemedical
"The emergence of oral small-molecule amylin programs as a potential market-expanding"
An oral small-molecule is a drug made of low-weight chemical compounds that can be swallowed as a pill or capsule and absorbed into the bloodstream. Think of it as a small key designed to fit and modulate a specific biological “lock” inside the body; for investors, these drugs often mean simpler manufacturing, clearer dosing and wider patient access compared with complex biologic therapies, so clinical success or failure can quickly affect a company’s value.
intellectual propertyfinancial
"high-impact innovation trends at the intersection of biotechnology, intellectual property,"
Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.
patentfinancial
"The critical role of patent strategy in determining long-term competitive advantage"
A patent is a government-granted right that gives an inventor exclusive control to make, use, sell or license a specific invention for a limited time, usually in exchange for publicly describing how it works. For investors it matters because a patent can act like a time-limited lock on a product or process — reducing competition, protecting future sales or licensing income, and often increasing a company’s value, while still being defeasible, time-bound and subject to legal challenge.
Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse report, “The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine.”
The report provides a comprehensive analysis of the rapidly evolving amylin drug landscape, a mechanism once considered commercially unviable that is now at the center of global pharmaceutical strategy.
Over the past eighteen months, more than $19 billion in deal value has been committed across the amylin space, with major pharmaceutical companies, including Novo Nordisk, Eli Lilly, Roche, Pfizer, and AbbVie, actively building positions.
The report highlights:
Nearly 40 amylin receptor agonist programs currently in development worldwide
The first GLP-1/amylin combination therapy approaching FDA decision
Clinical data demonstrating up to 20%+ weight loss with amylin-based therapies
The emergence of oral small-molecule amylin programs as a potential market-expanding force
The critical role of patent strategy in determining long-term competitive advantage
“We are witnessing the maturation of Amylin into the strategic bedrock of obesity therapeutics. In a world of converging efficacy, the value proposition is shifting from clinical data to patent depth. The winners won’t just be those with the best molecule, but those with the most sophisticated intellectual property architecture.” said Will Rosellini, Chief IP Officer at PatentVest.
The report also examines how the next 18 months, featuring major clinical readouts, regulatory decisions, and early-stage data, will reshape the competitive landscape.
PatentVest Pulse is an ongoing research series analyzing high-impact innovation trends at the intersection of biotechnology, intellectual property, and competitive strategy.
PatentVest provides strategic intelligence at the intersection of intellectual property, life sciences, and capital markets, helping investors and operators identify defensible innovation.
Media Contact:
For more information or inquiries, please contact info@patentvest.com.
FAQ
What does PatentVest say about the size of the amylin opportunity in the March 31, 2026 report (MDBH)?
The report quantifies the opportunity at about $19 billion in deals committed over the past 18 months. According to PatentVest, that figure reflects deal value across amylin programs and major pharma activity.
How many amylin programs does PatentVest report are in development as of March 31, 2026 (MDBH)?
PatentVest reports nearly 40 amylin receptor agonist programs currently in development worldwide. According to PatentVest, this count covers both biologics and early small-molecule efforts.
What clinical efficacy does the PatentVest Pulse cite for amylin-based therapies (MDBH)?
The report cites clinical data showing up to 20%+ weight loss with amylin-based therapies in trials. According to PatentVest, these results underpin growing commercial interest and combination development.
Is there a regulatory milestone for GLP-1/amylin combinations noted by PatentVest (MDBH)?
Yes — PatentVest notes the first GLP-1/amylin combination therapy is approaching an FDA decision. According to PatentVest, this decision is a near-term catalyst for the competitive landscape.
Does the March 31, 2026 PatentVest report discuss oral amylin programs and their market impact (MDBH)?
The report highlights emerging oral small-molecule amylin programs as potential market expanders. According to PatentVest, oral programs could broaden patient access and reshape competitive dynamics.
